Multiple Sclerosis Therapeutic Market (By Drug Class; By Route of Administration: Oral, Injectable; By Distribution Channel) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2024-2033

Multiple Sclerosis Therapeutic Market Size and Growth 2024 to 2033

The global multiple sclerosis therapeutic market size was estimated at USD 25.97 billion in 2023 and it is expected to surpass around USD 46.2 billion by 2033, poised to grow at a CAGR of 5.93% from 2024 to 2033. The multiple sclerosis (MS) therapeutic market has been experiencing significant growth over the past few years, driven by advancements in medical research, the development of novel therapies, and an increasing prevalence of the disease. Multiple sclerosis is a chronic, inflammatory autoimmune disease that affects the central nervous system, leading to a wide range of symptoms including physical, mental, and sometimes psychiatric problems. The therapeutic landscape for MS is diverse, encompassing disease-modifying therapies (DMTs), symptomatic treatments, and emerging gene and cell-based therapies.

Key Pointers

• North America dominated the global multiple sclerosis therapeutic market with the largest market share 39% in 2023.
• By Drug Class, the immunosuppressants segment contributed the largest market share of 61% in 2023.
• By Drug Class, the immunostimulants segment is anticipated to grow at a CAGR of 6.63% from 2024 to 2033.
• By Route of Administration, the injectable segment held the largest market share at 53% in 2023.
• By Route of Administration, the oral segment is estimated to expand the fastest CAGR of 7.03% during the forecast period.
• By Distribution Channel, the hospital pharmacies held the largest revenue share of 47% in 2023.

What are the Growth Factors of Multiple Sclerosis Therapeutic Market?

The growth of the multiple sclerosis (MS) therapeutic market is driven by the rising prevalence of MS globally is a significant contributor, as more patients require effective treatments. Advances in diagnostic technologies have also played a crucial role, enabling earlier and more accurate detection of the disease, which in turn drives the demand for novel therapies. The continuous evolution of research and development in the field has led to the introduction of innovative disease-modifying therapies (DMTs) and biologics, expanding the treatment options available. Additionally, increased investment in clinical trials and research, alongside growing healthcare expenditures, supports the development of new therapies and enhances market growth. The push towards personalized medicine and targeted therapies also aligns with the trend of providing more effective and individualized treatment options, further propelling the market forward.

What are the Trends in Multiple Sclerosis Therapeutic Market?

• Emergence of Oral Therapies: There is a growing shift towards oral disease-modifying therapies (DMTs) in the MS market. These therapies offer convenience and improved patient adherence compared to traditional injectable treatments.
• Advancements in Biologics: The development of biologics, including monoclonal antibodies and other targeted therapies, is becoming increasingly prevalent. These treatments are designed to specifically target and modify the underlying disease mechanisms in MS.
• Personalized Medicine: Tailoring treatment plans based on genetic, environmental, and lifestyle factors is gaining momentum. Personalized medicine aims to enhance the efficacy of therapies and minimize adverse effects by customizing treatment to individual patient profiles.
• Focus on Progressive MS: There is a growing emphasis on addressing progressive forms of MS, which have historically been harder to treat. New therapies are being developed to target progressive MS and improve outcomes for patients with this challenging form of the disease.
• Integration of Digital Health Tools: The use of digital health technologies, including mobile apps and telemedicine, is increasing. These tools help in monitoring disease progression, managing symptoms, and providing remote support, which enhances patient engagement and care.

What are the Key Challenges Faced by Multiple Sclerosis Therapeutic Market?

• High Cost of Therapies: The cost of innovative multiple sclerosis therapies, particularly biologics and new oral treatments, remains high. This can limit access for patients and strain healthcare systems, especially in regions with less healthcare funding.
• Variable Efficacy and Side Effects: Despite advances in treatment, therapies for MS can have varying levels of efficacy and may cause significant side effects. This variability can complicate treatment plans and affect patient adherence.
• Complexity of Disease Management: MS is a heterogeneous disease with a wide range of symptoms and disease courses. This complexity makes it challenging to develop one-size-fits-all treatments and requires personalized approaches, which can be difficult to implement effectively.
• Limited Treatment Options for Progressive MS: Effective treatments for progressive forms of MS, which include secondary progressive MS (SPMS) and primary progressive MS (PPMS), are still limited. This represents a significant unmet need in the therapeutic landscape.

Which Region Dominates the Multiple Sclerosis Therapeutic Market?

North America led the global multiple sclerosis therapeutic market with a 39% share in 2023. The region's growth is primarily due to the rising number of MS cases and the presence of advanced healthcare infrastructure.

What is the Contribution of North America to Multiple Sclerosis Therapeutic Market?

Europe Multiple Sclerosis Therapeutic Market Trends

In 2023, Europe emerged as a lucrative market for multiple sclerosis therapeutics, supported by its well-established healthcare infrastructure. The UK is expected to experience rapid growth in the market due to its advanced healthcare system, which facilitates precise diagnosis and tailored treatment options. Germany also held a significant market share in 2023, thanks to proactive government recommendations and favorable healthcare policies.

Asia-Pacific Multiple Sclerosis Therapeutic Market Trends

The Asia-Pacific market is projected to grow swiftly in the coming years, driven by increased government initiatives, a broader range of treatment options, and lower treatment costs. China held a notable market share in 2023, with its growing pharmaceutical industry and the establishment of the China National Registry of Central Nervous System Inflammatory Demyelinating Illnesses in 2021, which aims to provide comprehensive disease management. India also held a substantial market share, influenced by its expanding healthcare infrastructure and government initiatives promoting advanced technologies.

Drug Class Insights

In 2023, the immunosuppressants segment led the market with a dominant 61% share. These medications are crucial for managing multiple sclerosis by inhibiting the abnormal immune response associated with the disease. The expansion of this segment is supported by the growing approval of new products for MS. Immunosuppressants are favored for their low dosage requirements, reduced adverse effects, and high efficacy, driving their continued market growth.

The immunostimulants segment is anticipated to grow at a CAGR of 6.63% throughout the forecast period. These drugs enhance the immune system’s activity, which can be beneficial in multiple sclerosis by helping to counteract disease progression. Advances in research and technology are leading to the development of new immunostimulant therapies that target specific pathways involved in MS, offering promising new treatment options for patients.

Route of Administration Insights

In 2023, the injectable segment held the largest market share at 53%. This segment’s growth is attributed to the higher efficacy and convenience of injectable drugs compared to other methods of administration. Injectables are particularly effective in managing disease symptoms, contributing to their continued preference.

The oral segment, projected to grow at a CAGR of 7.03% during the forecast period, benefits from its convenience and ease of use. Oral medications eliminate the need for frequent, often painful injections, making them a preferred choice among patients seeking a more manageable treatment regimen.

Distribution Channel Insights

In 2023, hospital pharmacies dominated the market with a 47% share. This prominence is due to the growing significance of MS and the increasing number of inpatients. Hospitals are becoming central hubs for diagnosing and treating multiple sclerosis, leading to a higher distribution of therapeutics through their pharmacies.

Retail pharmacies are expected to grow at a CAGR of 6.43% during the forecast period. This growth is driven by the convenience and accessibility of retail pharmacies, making them a preferred choice for patients needing regular medication refills.

Who are the Top Manufactures in Multiple Sclerosis Therapeutic Market?

• Teva Pharmaceutical Industries Ltd.
• Pfizer Inc.
• Biogen
• Bayer AG
• Sanofi
• F. Hoffmann-La Roche Ltd
• Johnson & Johnson Services, Inc.
• Merck & Co., Inc.
• Takeda Pharmaceutical Company Limited.
• Horizon Therapeutics plc

Recent Developments

• In February 2024, Roche Pharma India announced the launch of Ocrevus, a significant addition to the multiple sclerosis (MS) therapeutic landscape in India. Ocrevus, a leading product in Roche's portfolio, is now available in over 100 countries. In India, it is approved for both primary progressive and relapsing forms of MS, addressing the needs of a diverse patient population.
• Also in February 2024, Neuraxpharm Group launched BRIUMVI in Europe. This new therapy is designed for adult patients suffering from relapsing forms of MS, offering an innovative treatment option to manage the disease and improve patient outcomes.
• In August 2023, the U.S. Food and Drug Administration (FDA) approved Tyruko, marking it as the first biosimilar to Tysabri. Tyruko is approved for treating various forms of relapsing MS, including relapsing-remitting disease, active secondary progressive disease, and clinically isolated syndrome. This approval expands treatment options for adults with relapsing forms of MS, providing a new approach to managing the condition.

Multiple Sclerosis Therapeutic Market Segmentation:

By Drug Class

• Immunosuppressants
• Immunostimulants

By Route of Administration

• Oral
• Injectable
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• E-Commerce

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa (MEA)